Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 153

1.

The neuropeptide receptor calcitonin receptor-like (CALCRL) is a potential therapeutic target in acute myeloid leukemia.

Angenendt L, Bormann E, Pabst C, Alla V, Görlich D, Braun L, Dohlich K, Schwöppe C, Bohlander SK, Arteaga MF, Wethmar K, Hartmann W, Angenendt A, Kessler T, Mesters RM, Stelljes M, Rothenberg-Thurley M, Spiekermann K, Hébert J, Sauvageau G, Valk PJM, Löwenberg B, Serve H, Müller-Tidow C, Lenz G, Wörmann BJ, Sauerland MC, Hiddemann W, Berdel WE, Krug U, Metzeler KH, Mikesch JH, Herold T, Schliemann C.

Leukemia. 2019 Jun 10. doi: 10.1038/s41375-019-0505-x. [Epub ahead of print]

PMID:
31182782
2.

Gadofosveset-enhanced MRI as simple surrogate parameter for real-time evaluation of the initial tumour vessel infarction by retargeted tissue factor tTF-NGR.

Höink A, Persigehl T, Kwiecien R, Balthasar M, Mesters R, Berdel W, Heindel W, Bremer C, Schwöppe C.

Oncol Lett. 2019 Jan;17(1):270-280. doi: 10.3892/ol.2018.9638. Epub 2018 Oct 29.

3.

Six versus eight doses of rituximab in patients with aggressive B cell lymphoma receiving six cycles of CHOP: results from the "Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas" (PETAL) trial.

Hüttmann A, Rekowski J, Müller SP, Hertenstein B, Franzius C, Mesters R, Weckesser M, Kroschinsky F, Kotzerke J, Ganser A, Bengel FM, La Rosée P, Freesmeyer M, Höffkes HG, Hertel A, Behringer D, Prange-Krex G, Griesshammer M, Holzinger J, Wilop S, Krohn T, Raghavachar A, Maschmeyer G, Brink I, Schroers R, Gaska T, Bernhard H, Giagounidis A, Schütte J, Dienst A, Hautzel H, Naumann R, Klein A, Hahn D, Pöpperl G, Grube M, Marienhagen J, Schwarzer A, Kurch L, Höhler T, Steiniger H, Nückel H, Südhoff T, Römer W, Brinkmann M, Ose C, Alashkar F, Schmitz C, Dürig J, Hoelzer D, Jöckel KH, Klapper W, Dührsen U.

Ann Hematol. 2019 Apr;98(4):897-907. doi: 10.1007/s00277-018-3578-0. Epub 2019 Jan 4.

PMID:
30610279
4.

Aminopeptidase N (CD13): Expression, Prognostic Impact, and Use as Therapeutic Target for Tissue Factor Induced Tumor Vascular Infarction in Soft Tissue Sarcoma.

Kessler T, Baumeier A, Brand C, Grau M, Angenendt L, Harrach S, Stalmann U, Schmidt LH, Gosheger G, Hardes J, Andreou D, Dreischalück J, Lenz G, Wardelmann E, Mesters RM, Schwöppe C, Berdel WE, Hartmann W, Schliemann C.

Transl Oncol. 2018 Dec;11(6):1271-1282. doi: 10.1016/j.tranon.2018.08.004. Epub 2018 Aug 17.

5.

Adjuvant chemotherapy-Radiotherapy-Chemotherapy sandwich protocol in resectable soft tissue sarcoma: An updated single-center analysis of 104 cases.

Schliemann C, Kerkhoff A, Hesse P, Bröckling S, Hardes J, Streitbürger A, Andreou D, Gosheger G, Elges S, Wardelmann E, Hartmann W, Mesters R, Lenz G, Willich N, Kriz J, Eich H, Berdel WE, Kessler T.

PLoS One. 2018 May 22;13(5):e0197315. doi: 10.1371/journal.pone.0197315. eCollection 2018.

6.

Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas (PETAL): A Multicenter, Randomized Phase III Trial.

Dührsen U, Müller S, Hertenstein B, Thomssen H, Kotzerke J, Mesters R, Berdel WE, Franzius C, Kroschinsky F, Weckesser M, Kofahl-Krause D, Bengel FM, Dürig J, Matschke J, Schmitz C, Pöppel T, Ose C, Brinkmann M, La Rosée P, Freesmeyer M, Hertel A, Höffkes HG, Behringer D, Prange-Krex G, Wilop S, Krohn T, Holzinger J, Griesshammer M, Giagounidis A, Raghavachar A, Maschmeyer G, Brink I, Bernhard H, Haberkorn U, Gaska T, Kurch L, van Assema DME, Klapper W, Hoelzer D, Geworski L, Jöckel KH, Scherag A, Bockisch A, Rekowski J, Hüttmann A; PETAL Trial Investigators.

J Clin Oncol. 2018 Jul 10;36(20):2024-2034. doi: 10.1200/JCO.2017.76.8093. Epub 2018 May 11.

PMID:
29750632
7.

An atlas of bloodstream-accessible bone marrow proteins for site-directed therapy of acute myeloid leukemia.

Angenendt L, Reuter S, Kentrup D, Benk AS, Neumann F, Hüve J, Martens AC, Schwöppe C, Kessler T, Schmidt LH, Sauer T, Brand C, Mikesch JH, Lenz G, Mesters RM, Müller-Tidow C, Hartmann W, Wardelmann E, Neri D, Berdel WE, Roesli C, Schliemann C.

Leukemia. 2018 Feb;32(2):510-519. doi: 10.1038/leu.2017.208. Epub 2017 Jun 30.

PMID:
28663580
8.

Autologous Stem Cell Transplantation in Multiple Myeloma in the Era of Novel Drug Induction: A Retrospective Single-Center Analysis.

Thoennissen GB, Görlich D, Bacher U, Aufenberg T, Hüsken AC, Hansmeier AA, Evers G, Mikesch JH, Fritz F, Bokemeyer C, Müller-Tidow C, Stelljes M, Mesters RM, Krug U, Kropff MH, Thoennissen NH, Berdel WE.

Acta Haematol. 2017;137(3):163-172. doi: 10.1159/000463534. Epub 2017 Apr 12.

9.

Rare genetic variants in SMAP1, B3GAT2, and RIMS1 contribute to pediatric venous thromboembolism.

Rühle F, Witten A, Barysenka A, Huge A, Arning A, Heller C, Krümpel A, Mesters R, Franke A, Lieb W, Riemenschneider M, Hiersche M, Limperger V, Nowak-Göttl U, Stoll M.

Blood. 2017 Feb 9;129(6):783-790. doi: 10.1182/blood-2016-07-728840. Epub 2016 Dec 23.

PMID:
28011674
10.

Impact of high risk thrombophilia status on recurrence among children and adults with VTE: An observational multicenter cohort study.

Brüwer G, Limperger V, Kenet G, Klostermeier UC, Shneyder M, Degenhardt F, Finckh U, Heller C, Holzhauer S, Trappe R, Kentouche K, Knoefler R, Kurnik K, Krümpel A, Lauten M, Manner D, Mesters R, Junker R, Nowak-Göttl U.

Blood Cells Mol Dis. 2016 Nov;62:24-31. doi: 10.1016/j.bcmd.2016.10.024. Epub 2016 Nov 5.

PMID:
27838551
11.

Outcome of allogeneic stem cell transplantation for AML and myelodysplastic syndrome in elderly patients (⩾60 years).

Pohlen M, Groth C, Sauer T, Görlich D, Mesters R, Schliemann C, Lenz G, Müller-Tidow C, Büchner T, Berdel WE, Stelljes M.

Bone Marrow Transplant. 2016 Nov;51(11):1441-1448. doi: 10.1038/bmt.2016.156. Epub 2016 Jun 13.

PMID:
27295269
12.

Prothrombin and factor X are elevated in multiple sclerosis patients.

Göbel K, Kraft P, Pankratz S, Gross CC, Korsukewitz C, Kwiecien R, Mesters R, Kehrel BE, Wiendl H, Kleinschnitz C, Meuth SG.

Ann Neurol. 2016 Dec;80(6):946-951. doi: 10.1002/ana.24807. Epub 2016 Nov 14.

PMID:
27774643
13.

Combinatorial effects of doxorubicin and retargeted tissue factor by intratumoral entrapment of doxorubicin and proapoptotic increase of tumor vascular infarction.

Stucke-Ring J, Ronnacker J, Brand C, Höltke C, Schliemann C, Kessler T, Schmidt LH, Harrach S, Mantke V, Hintelmann H, Hartmann W, Wardelmann E, Lenz G, Wünsch B, Müller-Tidow C, Mesters RM, Schwöppe C, Berdel WE.

Oncotarget. 2016 Dec 13;7(50):82458-82472. doi: 10.18632/oncotarget.12559.

14.

Impact of gender on safety and efficacy of Rivaroxaban in adolescents & young adults with venous thromboembolism.

Krause M, Henningsen A, Torge A, Juhl D, Junker R, Kenet G, Kowalski D, Limperger V, Mesters R, Anonymous, Rocke A, Shneyder M, Clausnizer H, Schiesewitz H, Nowak-Göttl U.

Thromb Res. 2016 Dec;148:145-151. doi: 10.1016/j.thromres.2016.09.007. Epub 2016 Sep 13. No abstract available.

PMID:
27687905
15.

Ciprofloxacin versus colistin prophylaxis during neutropenia in acute myeloid leukemia: two parallel patient cohorts treated in a single center.

Pohlen M, Marx J, Mellmann A, Becker K, Mesters RM, Mikesch JH, Schliemann C, Lenz G, Müller-Tidow C, Büchner T, Krug U, Stelljes M, Karch H, Peters G, Gerth HU, Görlich D, Berdel WE.

Haematologica. 2016 Oct;101(10):1208-1215. Epub 2016 Jul 28.

16.

Impact of high-risk thrombophilia status on recurrence among children with a first non-central-venous-catheter-associated VTE: an observational multicentre cohort study.

Limperger V, Kenet G, Goldenberg NA, Heller C, Holzhauer S, Junker R, Klostermeier UC, Knoefler R, Kurnik K, Krümpel A, Mesters R, Stach M, Young G, Nowak-Göttl U.

Br J Haematol. 2016 Oct;175(1):133-40. doi: 10.1111/bjh.14192. Epub 2016 Jun 22.

PMID:
27329967
17.

Age, not therapy intensity, determines outcomes of adults with acute myeloid leukemia.

Büchner T, Krug UO, Peter Gale R, Heinecke A, Sauerland MC, Haferlach C, Schnittger S, Haferlach T, Müller-Tidow C, Stelljes M, Mesters RM, Serve HL, Braess J, Spiekermann K, Staib P, Grüneisen A, Reichle A, Balleisen L, Eimermacher H, Giagounidis A, Rasche H, Lengfelder E, Görlich D, Faldum A, Köpcke W, Hehlmann R, Wörmann BJ, Berdel WE, Hiddemann W.

Leukemia. 2016 Aug;30(8):1781-4. doi: 10.1038/leu.2016.54. Epub 2016 Mar 11. No abstract available.

PMID:
26965440
18.

NG2 proteoglycan as a pericyte target for anticancer therapy by tumor vessel infarction with retargeted tissue factor.

Brand C, Schliemann C, Ring J, Kessler T, Bäumer S, Angenendt L, Mantke V, Ross R, Hintelmann H, Spieker T, Wardelmann E, Mesters RM, Berdel WE, Schwöppe C.

Oncotarget. 2016 Feb 9;7(6):6774-89. doi: 10.18632/oncotarget.6725.

19.

Tumor Growth Inhibition via Occlusion of Tumor Vasculature Induced by N-Terminally PEGylated Retargeted Tissue Factor tTF-NGR.

Brand C, Fröhlich M, Ring J, Schliemann C, Kessler T, Mantke V, König S, Lücke M, Mesters RM, Berdel WE, Schwöppe C.

Mol Pharm. 2015 Oct 5;12(10):3749-58. doi: 10.1021/acs.molpharmaceut.5b00508. Epub 2015 Aug 31.

PMID:
26310827
20.

Assessment of Hemostasis after Plasma Exchange Using Rotational Thrombelastometry (ROTEM).

Thölking G, Mesters R, Dittrich R, Pavenstädt H, Kümpers P, Reuter S.

PLoS One. 2015 Jun 29;10(6):e0130402. doi: 10.1371/journal.pone.0130402. eCollection 2015.

21.

Low-Energy Ultrasound Treatment Improves Regional Tumor Vessel Infarction by Retargeted Tissue Factor.

Brand C, Dencks S, Schmitz G, Mühlmeister M, Stypmann J, Ross R, Hintelmann H, Schliemann C, Müller-Tidow C, Mesters RM, Berdel WE, Schwöppe C.

J Ultrasound Med. 2015 Jul;34(7):1227-36. doi: 10.7863/ultra.34.7.1227.

PMID:
26112625
22.

Implantation of left ventricular assist devices under extracorporeal life support in patients with heparin-induced thrombocytopenia.

Hillebrand J, Sindermann J, Schmidt C, Mesters R, Martens S, Scherer M.

J Artif Organs. 2015 Dec;18(4):291-9. doi: 10.1007/s10047-015-0846-9. Epub 2015 Jun 5.

PMID:
26044781
23.

The syndrome of hemophagocytic lymphohistiocytosis in primary immunodeficiencies: implications for differential diagnosis and pathogenesis.

Bode SF, Ammann S, Al-Herz W, Bataneant M, Dvorak CC, Gehring S, Gennery A, Gilmour KC, Gonzalez-Granado LI, Groß-Wieltsch U, Ifversen M, Lingman-Framme J, Matthes-Martin S, Mesters R, Meyts I, van Montfrans JM, Pachlopnik Schmid J, Pai SY, Soler-Palacin P, Schuermann U, Schuster V, Seidel MG, Speckmann C, Stepensky P, Sykora KW, Tesi B, Vraetz T, Waruiru C, Bryceson YT, Moshous D, Lehmberg K, Jordan MB, Ehl S; Inborn Errors Working Party of the EBMT.

Haematologica. 2015 Jul;100(7):978-88. doi: 10.3324/haematol.2014.121608. Epub 2015 May 28.

24.

Delayed Diagnosis of Platelet-type von Willebrand Disease in a 72-year-old Lady.

Maurer M, Mesters R, Schneppenheim R, Streif W.

Klin Padiatr. 2015 May;227(3):171-2. doi: 10.1055/s-0035-1548915. Epub 2015 May 18. No abstract available.

PMID:
25985451
25.

Platelet-type von Willebrand Disease: Diagnostic Challenges. Flaws and Pitfalls Experienced in the THROMKID Quality Project.

Maurer M, Mesters R, Schneppenheim R, Knoefler R, Streif W.

Klin Padiatr. 2015 May;227(3):131-6. doi: 10.1055/s-0035-1548838. Epub 2015 May 18. Review.

PMID:
25985448
26.

Potentiating the activity of rituximab against mantle cell lymphoma in mice by targeting interleukin-2 to the neovasculature.

Börschel N, Schwöppe C, Zerbst C, Angenendt L, Kessler T, Klapper W, Giovannoni L, Elia G, Neri D, Berdel WE, Mesters RM, Schliemann C.

Leuk Res. 2015 Jul;39(7):739-48. doi: 10.1016/j.leukres.2015.04.005. Epub 2015 Apr 17.

PMID:
25934049
27.

Targeting interleukin-2 to the bone marrow stroma for therapy of acute myeloid leukemia relapsing after allogeneic hematopoietic stem cell transplantation.

Schliemann C, Gutbrodt KL, Kerkhoff A, Pohlen M, Wiebe S, Silling G, Angenendt L, Kessler T, Mesters RM, Giovannoni L, Schäfers M, Altvater B, Rossig C, Grünewald I, Wardelmann E, Köhler G, Neri D, Stelljes M, Berdel WE.

Cancer Immunol Res. 2015 May;3(5):547-56. doi: 10.1158/2326-6066.CIR-14-0179. Epub 2015 Feb 11.

28.

Thromboembolic events in Fabry disease and the impact of factor V Leiden.

Lenders M, Karabul N, Duning T, Schmitz B, Schelleckes M, Mesters R, Hense HW, Beck M, Brand SM, Brand E.

Neurology. 2015 Mar 10;84(10):1009-16. doi: 10.1212/WNL.0000000000001333. Epub 2015 Feb 6.

PMID:
25663229
29.

Treatment strategies in patients with AML or high-risk myelodysplastic syndrome relapsed after Allo-SCT.

Sauer T, Silling G, Groth C, Rosenow F, Krug U, Görlich D, Evers G, Albring J, Besoke R, Mesters RM, Müller-Tidow C, Kessler T, Büchner T, Berdel WE, Stelljes M.

Bone Marrow Transplant. 2015 Apr;50(4):485-92. doi: 10.1038/bmt.2014.300. Epub 2015 Jan 19.

PMID:
25599163
30.

Role of protein S deficiency in children with venous thromboembolism. An observational international cohort study.

Klostermeier UC, Limperger V, Kenet G, Kurnik K, Alhenc Gelas M, Finckh U, Junker R, Heller C, Zieger B, Knöfler R, Holzhauer S, Mesters R, Krümpel A, Nowak-Göttl U.

Thromb Haemost. 2015 Feb;113(2):426-33. doi: 10.1160/TH14-06-0533. Epub 2014 Oct 2.

PMID:
25272994
31.

Comparison of manual and semi-automatic measuring techniques in MSCT scans of patients with lymphoma: a multicentre study.

Höink AJ, Weßling J, Koch R, Schülke C, Kohlhase N, Wassenaar L, Mesters RM, D'Anastasi M, Fabel M, Wulff A, Pinto dos Santos D, Kießling A, Graser A, Dicken V, Karpitschka M, Bornemann L, Heindel W, Buerke B.

Eur Radiol. 2014 Nov;24(11):2709-18. doi: 10.1007/s00330-014-3283-x. Epub 2014 Sep 6.

PMID:
25192795
32.

Clinical and laboratory characteristics of children with venous thromboembolism and protein C-deficiency: an observational Israeli-German cohort study.

Limperger V, Klostermeier UC, Kenet G, Holzhauer S, Alhenc Gelas M, Finckh U, Junker R, Heller C, Zieger B, Kurnik K, Knöfler R, Mesters R, Halimeh S, Nowak-Göttl U.

Br J Haematol. 2014 Nov;167(3):385-93. doi: 10.1111/bjh.13039. Epub 2014 Jul 18.

PMID:
25039884
33.

Clinical and laboratory characteristics of paediatric and adolescent index cases with venous thromboembolism and antithrombin deficiency. An observational multicentre cohort study.

Limperger V, Franke A, Kenet G, Holzhauer S, Picard V, Junker R, Heller C, Gille C, Manner D, Kurnik K, Knoefler R, Mesters R, Halimeh S, Nowak-Göttl U.

Thromb Haemost. 2014 Sep 2;112(3):478-85. doi: 10.1160/TH14-02-0149. Epub 2014 Jun 26.

PMID:
24966143
34.

[Bridging: Perioperative management of chronic anticoagulation or antiplatelet therapy].

Nowak-Göttl U, Langer F, Limperger V, Mesters R, Trappe RU.

Dtsch Med Wochenschr. 2014 Jun;139(24):1301-6. doi: 10.1055/s-0034-1370110. Epub 2014 Jun 3. Review. German.

PMID:
24892468
35.

Therapy response evaluation of malignant lymphoma in a multicenter study: comparison of manual and semiautomatic measurements in CT.

Weßling J, Schülke C, Koch R, Kohlhase N, Wassenaar L, Mesters R, Höink AJ, D Anastasi M, Karpitschka M, Fabel M, Wulff AM, Pinto dos Santos D, Kiessling A, Graser A, Bornemann L, Dicken V, Heindel W, Buerke B.

Rofo. 2014 Aug;186(8):768-79. doi: 10.1055/s-0033-1356424. Epub 2014 Feb 4.

36.

Significant dose Escalation of Idarubicin in the treatment of aggressive Non- Hodgkin Lymphoma leads to increased hematotoxicity without improvement in efficacy in comparison to standard CHOEP-14: 9-year follow up results of the CIVEP trial of the DSHNHL.

Hohloch K, Zwick C, Ziepert M, Hasenclever D, Kaiser U, Engert A, Höffkes HG, Kroschinsky F, Mesters R, Feller AC, Löffler M, Trümper L, Pfreundschuh M; German High-Grade Non-Hodgkin´s Lymphoma Study Group (DSHNHL).

Springerplus. 2014 Jan 3;3:5. doi: 10.1186/2193-1801-3-5. eCollection 2014 Jan 3.

37.

Non-invasive monitoring of tumor-vessel infarction by retargeted truncated tissue factor tTF-NGR using multi-modal imaging.

Persigehl T, Ring J, Bremer C, Heindel W, Holtmeier R, Stypmann J, Claesener M, Hermann S, Schäfers M, Zerbst C, Schliemann C, Mesters RM, Berdel WE, Schwöppe C.

Angiogenesis. 2014 Jan;17(1):235-46. doi: 10.1007/s10456-013-9391-4. Epub 2013 Oct 18.

PMID:
24136410
38.

Visceral leishmaniasis clinically mimicking lymphoma.

Evers G, Pohlen M, Berdel WE, Thoennissen NH, Titze U, Köhler G, Weckesser M, Anthoni C, Mesters RM.

Ann Hematol. 2014 May;93(5):885-7. doi: 10.1007/s00277-013-1896-9. Epub 2013 Sep 6. No abstract available.

PMID:
24061787
39.

Plasma protein S residues 37-50 mediate its binding to factor Va and inhibition of blood coagulation.

Heeb MJ, Mesters RM, Fernández JA, Hackeng TM, Nakasone RK, Griffin JH.

Thromb Haemost. 2013 Aug;110(2):275-82. doi: 10.1160/TH12-12-0953. Epub 2013 May 23.

40.

DexaBEAM versus ICE salvage regimen prior to autologous transplantation for relapsed or refractory aggressive peripheral T cell lymphoma: a retrospective evaluation of parallel patient cohorts of one center.

Mikesch JH, Kuhlmann M, Demant A, Krug U, Thoennissen GB, Schmidt E, Kessler T, Schliemann C, Pohlen M, Mohr M, Evers G, Köhler G, Wessling J, Mesters R, Müller-Tidow C, Berdel WE, Thoennissen NH.

Ann Hematol. 2013 Aug;92(8):1041-8. doi: 10.1007/s00277-013-1738-9. Epub 2013 Mar 27.

PMID:
23532626
41.

Anticancer therapy by tumor vessel infarction with polyethylene glycol conjugated retargeted tissue factor.

Schwöppe C, Zerbst C, Fröhlich M, Schliemann C, Kessler T, Liersch R, Overkamp L, Holtmeier R, Stypmann J, Dreiling A, König S, Höltke C, Lücke M, Müller-Tidow C, Mesters RM, Berdel WE.

J Med Chem. 2013 Mar 28;56(6):2337-47. doi: 10.1021/jm301669z. Epub 2013 Mar 15.

PMID:
23496322
42.

CD34(+) lineage specific donor cell chimerism for the diagnosis and treatment of impending relapse of AML or myelodysplastic syndrome after allo-SCT.

Rosenow F, Berkemeier A, Krug U, Müller-Tidow C, Gerss J, Silling G, Groth C, Wieacker P, Bogdanova N, Mesters R, Büchner T, Kienast J, Berdel WE, Stelljes M.

Bone Marrow Transplant. 2013 Aug;48(8):1070-6. doi: 10.1038/bmt.2013.2. Epub 2013 Feb 4.

PMID:
23376821
43.

Role of reduced ADAMTS13 in arterial ischemic stroke: a pediatric cohort study.

Lambers M, Goldenberg NA, Kenet G, Kirkham FJ, Manner D, Bernard T, Mesters RM, Junker R, Stoll M, Nowak-Göttl U.

Ann Neurol. 2013 Jan;73(1):58-64. doi: 10.1002/ana.23735. Epub 2012 Dec 7.

44.

Induced lymphatic sinus hyperplasia in sentinel lymph nodes by VEGF-C as the earliest premetastatic indicator.

Liersch R, Hirakawa S, Berdel WE, Mesters RM, Detmar M.

Int J Oncol. 2012 Dec;41(6):2073-8. doi: 10.3892/ijo.2012.1665. Epub 2012 Oct 16.

45.

Analysis of a novel highly metastatic melanoma cell line identifies osteopontin as a new lymphangiogenic factor.

Liersch R, Shin JW, Bayer M, Schwöppe C, Schliemann C, Berdel WE, Mesters R, Detmar M.

Int J Oncol. 2012 Oct;41(4):1455-63. doi: 10.3892/ijo.2012.1548. Epub 2012 Jul 6.

46.

MSCT follow-up in malignant lymphoma: comparison of manual linear measurements with semi-automated lymph node analysis for therapy response classification.

Weßling J, Puesken M, Koch R, Kohlhase N, Persigehl T, Mesters R, Heindel W, Buerke B.

Rofo. 2012 Sep;184(9):795-804. Epub 2012 May 22.

PMID:
22618478
47.

Inherited thrombophilia in children with venous thromboembolism and the familial risk of thromboembolism: an observational study.

Holzhauer S, Goldenberg NA, Junker R, Heller C, Stoll M, Manner D, Mesters R, Krümpel A, Stach M, Nowak-Göttl U.

Blood. 2012 Aug 16;120(7):1510-5. doi: 10.1182/blood-2012-01-405514. Epub 2012 May 11.

48.

POEMS syndrome treated with melphalan high-dose therapy and autologous blood stem cell transplantation: a single-institution experience.

Thoennissen GB, Thoennissen NH, Fritz F, Hilbig A, Kerkhoff A, Liersch R, Krug U, Koschmieder S, Müller-Tidow C, Mesters R, Kropff M, Berdel WE.

Ann Hematol. 2012 Sep;91(9):1419-25. doi: 10.1007/s00277-012-1473-7. Epub 2012 Apr 29.

PMID:
22543828
49.

Osteopontin is a prognostic factor for survival of acute myeloid leukemia patients.

Liersch R, Gerss J, Schliemann C, Bayer M, Schwöppe C, Biermann C, Appelmann I, Kessler T, Löwenberg B, Büchner T, Hiddemann W, Müller-Tidow C, Berdel WE, Mesters R.

Blood. 2012 May 31;119(22):5215-20. doi: 10.1182/blood-2011-11-389692. Epub 2012 Apr 17.

PMID:
22510874
50.

High-dose chemotherapy with autologous PBSC transplantation for poor prognosis germ cell tumors: a retrospective monocenter analysis of 44 cases.

Mohr M, Hartig I, Kessler T, Hamisch C, Kliesch S, Krug U, Spieker T, Semik M, Wiebe K, Pühse G, Hertle L, Liersch R, Müller-Tidow C, Mesters RM, Berdel WE.

Bone Marrow Transplant. 2012 Oct;47(10):1321-5. doi: 10.1038/bmt.2012.14. Epub 2012 Feb 13.

PMID:
22327130

Supplemental Content

Loading ...
Support Center